Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation

Area of Science:

• Neuroscience
• Immunology
• Hematology

Background:

• High-dose chemotherapy with autologous hematopoietic stem cell transplantation (HSCT) is used for severe multiple sclerosis (MS).
• Historically, HSCT for MS has yielded minor to moderate treatment effects, particularly in progressive cases with long disease duration.

Purpose of the Study:

• To evaluate the efficacy of HSCT in young patients with severe, malignant relapsing-remitting MS.
• To determine if HSCT can provide significant clinical improvement beyond previous reports for this specific MS subtype.

Main Methods:

• HSCT was performed on nine young patients diagnosed with malignant relapsing-remitting MS between 2004 and 2008.
• Inclusion criteria included short disease duration, frequent severe relapses, and potential for recovery post-immunosuppression.

Main Results:

• Patients had a median age of 27, MS duration of 26 months, and high relapse rates (10/year) pre-HSCT.
• Median Expanded Disability Status Scale (EDSS) improved from 7.0 to 2.0 post-HSCT, with a significant reduction in relapse frequency.
• One patient experienced a mild relapse 7 months post-HSCT, but all others remained stable.

Conclusions:

• HSCT appears to be an effective treatment for malignant relapsing-remitting MS.
• Current treatment criteria for HSCT in MS are suggested to be appropriate for this aggressive disease course.